|Table of Contents|

The predictive value of the number of pelvic lymph node metastasis on the prognosis of operable cervical squamous cancer patients(stage Ⅰb1 to Ⅱa2)

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 15
Page:
2904-2909
Research Field:
Publishing date:

Info

Title:
The predictive value of the number of pelvic lymph node metastasis on the prognosis of operable cervical squamous cancer patients(stage Ⅰb1 to Ⅱa2)
Author(s):
HUANG Fengxian1; LI Bin2; CAO Ximing1; JIN Wen2
1.Department of Radiotherapy;2.Department of Gynecology,Shaanxi Provincial People's Hospital,Shaanxi Xi'an 710068,China.
Keywords:
cervical squamous cancer; number of pelvic lymph node metastasis; nLNM; prognostic predictionModern Oncology 2023; 31(15)：2904-2909
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2023.15.026
Abstract:
Objective：To validate and evaluate the number of pelvic lymph node metastasis (nLNM) for prognostic prediction value in patients with operable cervical squamous cancer（stageⅠb1 toⅡa2).Methods：Patients with operable cervical squamous cancer (Ⅰb1 toⅡa2 stage) who fulfilled the inclusion and exclusion criteria were identified from the electronic database of our hospital from January 1,2010 to December 31,2017.Then the information of clinical and pathological characteristics,adjuvant therapies and survival outcomes were reviewed and analyzed.Results:A total of 108 patients were involved in this study,including 67 cases (62.04%) with nLNM ≤2 (N1 group) and 41 cases (37.96%) with nLNM ＞2 (N2 group).Significant differences were found between N1 and N2 groups in the depth of cervical stromal invasion (DSI),primary tumor size,2009 FIGO stage (P＜0.05).The 5-year overall survival (OS) for the entire group was 71.3%.The 5-year OS were 82.6% and 62.9% for the patients with LVSI-negative and LVSI-positive,respectively.The 5-year OS were 80.9% and 63.9% for the patients with DSI ≤1/2 and ＞1/2,respectively.The 5-year OS were 81.3% and 63.3% for the patients with tumor size ≤4 cm and ＞4 cm,respectively.The 5-year OS were 80.6% and 56.1% for the patients with N1 and N2 groups,respectively.All above differences were statistically significant (P＜0.05).In univariate analysis,LVSI,tumor size,nLNM and 2009 FIGO stage were prognostic factors for 5-year OS in operable cervical squamous cancer.Multivariate analysis further revealed that nLNM was also the independent prognostic factor for 5-year OS in patients with cervical squamous cancer,and the adjusted hazard ratio was 2.455 (95%CI:1.191~5.059).Conclusion:The number of pelvic lymph node metastasis was a better marker for predicting prognosis in patients with operable cervical squamous cancer（stageⅠb1 toⅡa2）,which may have an more important role in FIGO 2018 stage system of cervical cancer.

References:

［1］ ARBYN M,WEIDERPASS E,BRUNI L,et al.Estimates of incidence and mortality of cervical cancer in 2018:a worldwide analysis［J］.Lancet Glob Health,2020,8(2):e191-e203.
［2］ WRIGHT JD,MATSUO K,HUANG Y,et al.Prognostic performance of the 2018 international federation of gynecology and obstetrics cervical cancer staging guidelines［J］.Obstet Gynecol,2019,134(1):49-57.
［3］ WANG W,ZHANG F,HU K,et al.Image-guided,intensity-modulated radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer［J］.Gynecol Oncol,2018,151(3):444-448.
［4］ JOO JH,KIM YS,NAM JH.Prognostic significance of lymph node ratio in node-positive cervical cancer patients［J］.Medicine (Baltimore),2018,97(30):e11711.
［5］ MATSUO K,MACHIDA H,MANDELBAUM RS,et al.Validation of the 2018 FIGO cervical cancer staging system［J］.Gynecol Oncol,2019,152(1):87-93.
［6］ LI A,WANG L,JIANG Q,et al.Risk stratification based on metastatic pelvic lymph node status in stage IIIC1p cervical cancer［J］.Cancer Manag Res,2020,12:6431-6439.
［7］ WIDSCHWENDTER P,JANNI W,SCHOLZ C,et al.Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer［J］.Arch Gynecol Obstet,2019,300(6):1709-1718.
［8］ PEDONE AL,CARBONE V,GALLOTTA V,et al.Should the number of metastatic pelvic lymph nodes be integrated into the 2018 Figo staging classification of early stage cervical cancer［J］.Cancers (Basel),2020,12(6)：1-12.
［9］ MCCOMAS KN,TORGESON AM,AGER BJ,et al.The variable impact of positive lymph nodes in cervical cancer:Implications of the new FIGO staging system［J］.Gynecol Oncol,2020,156(1):85-92.
［10］ GUO Q,ZHU J,WU Y,et al.Validation of the prognostic value of various lymph node staging systems for cervical squamous cell carcinoma following radical surgery:a single-center analysis of 3 732 patients［J］.Ann Transl Med,2020,8(7):485.
［11］ TEICHGRAEBER DC,GUIRGUIS MS,WHITMAN GJ.Breast cancer staging:Updates in the AJCC cancer staging manual,8th edition,and current challenges for radiologists,from the AJR special series on cancer staging［J］.AJR Am J Roentgenol,2021,217(2):278-290.
［12］ OZAWA H,KAWAKUBO H,TAKEUCHI M,et al.Prognostic significance of the number and extent of metastatic lymph nodes in patients with esophageal cancer:Comparison of the Union for International Cancer Control 8th Edition and Japan Esophageal Society Japanese Classification of Esophageal Cancer 11th Edition Classifications for Esophageal Cancer［J］.Ann Surg Oncol,2021,28(11):6355-6363.
［13］ ASANO D,NARA S,KISHI Y,et al.A single-institution validation study of lymph node staging by the AJCC 8th edition for patients with pancreatic head cancer:A proposal to subdivide the N2 category［J］.Ann Surg Oncol,2019,26(7):2112-2120.
［14］ YAN DD,TANG Q,TU YQ,et al.A comprehensive analysis of the factors of positive pelvic lymph nodes on survival of cervical cancer patients with 2018 FIGO stage IIIC1p［J］.Cancer Manag Res,2019,11:4223-4230.
［15］ YAN DD,TANG Q,CHEN JH,et al.Prognostic value of the 2018 FIGO staging system for cervical cancer patients with surgical risk factors［J］.Cancer Manag Res,2019,11:5473-5480.
［16］ OLTHOF EP,MOM CH,SNIJDERS M,et al.The prognostic value of the number of positive lymph nodes and the lymph node ratio in early-stage cervical cancer［J］.Acta Obstet Gynecol Scand,2022,101(5):550-557.
［17］ ASLAN K,HABERAL A,AKILLI H,et al.Prognostic value of the number of the metastatic lymph nodes in locally early-stage cervical cancer:squamous cell carcinoma versus non-squamous cell carcinoma［J］.Arch Gynecol Obstet,2021,304(5):1279-1289.
［18］ KWON J,EOM KY,KIM YS,et al.The prognostic impact of the number of metastatic lymph nodes and a new prognostic scoring system for recurrence in early-stage cervical cancer with high risk factors:A multicenter cohort study (KROG 15-04)［J］.Cancer Res Treat,2018,50(3):964-974.
［19］ ZHOU J,WU SG,SUN JY,et al.Incorporation of the number of positive lymph nodes leads to better prognostic discrimination of node-positive early stage cervical cancer［J］.Oncotarget,2017,8(16):26057-26065.
［20］ TEN EM,HINTEN F,SMITS A,et al.Does the new FIGO 2018 staging system allow better prognostic differentiation in early stage cervical cancer? A Dutch nationwide cohort study［J］.Cancers (Basel),2022,14(13):1-13.
［21］ ZHONG ML,WANG YN,LIANG MR,et al.Consolidation chemotherapy in early-stage cervical cancer patients with lymph node metastasis after radical hysterectomy［J］.Int J Gynecol Cancer,2020,30(5):602-606.
［22］ WANG C,FU C,MA C,et al.The effectiveness of consolidation chemotherapy in high-risk early-stage cervical cancer patients following concurrent chemoradiation after radical surgery［J］.Jpn J Clin Oncol,2023,53(2):122-129.

Memo

Memo:
陕西省重点研发计划项目（编号：2022SF-489）；陕西省人民医院科技发展孵化基金项目（编号：2021YJY-43）；陕西省人民医院科技人才支持计划项目（编号：2022JY-24）
Last Update: 2023-06-30